Invesco Dorsey Wright Healthcare Momentum ETF(PTH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PTH Invesco Dorsey Wright Healthcare Momentum ETF

Market Closed 12-12 16:00:00 EST

52.36

+0.13

+0.25%

盘后52.34

-0.02-0.04%

16:10 EST

High52.68	Low52.16	Vol5.22K
Open52.55	D1 Closing52.23	Amplitude1.00%
Mkt Cap131.94M	Tradable Cap131.94M	Total Shares2.52M
T/O274.04K	T/O Rate0.21%	Tradable Shares2.52M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PTH","market":"US","secType":"STK","nameCN":"Invesco Dorsey Wright Healthcare Momentum ETF","latestPrice":52.3591,"timestamp":1765573200000,"preClose":52.2294,"halted":0,"volume":5217,"hourTrading":{"tag":"盘后","latestPrice":52.34,"preClose":52.3591,"latestTime":"16:10 EST","volume":15,"amount":784.8546,"timestamp":1765573804094},"delay":0,"floatShares":2520000,"shares":2520000,"eps":3.057033,"marketStatus":"Market Closed","change":0.1297,"latestTime":"12-12 16:00:00 EST","open":52.55,"high":52.6799,"low":52.16,"amount":274036.307298,"amplitude":0.009954,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":3.057033,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":52.2294,"sharesOutstanding":2520000,"nav":52.22597,"aum":131930604.24,"bidAskSpread":0.00249,"preHourTrading":{"tag":"盘前","latestPrice":52.2294,"preClose":52.2294,"latestTime":"08:55 EST","volume":1,"amount":52.2294,"timestamp":1765547739058},"postHourTrading":{"tag":"盘后","latestPrice":52.34,"preClose":52.3591,"latestTime":"16:10 EST","volume":15,"amount":784.8546,"timestamp":1765573804094},"volumeRatio":0.43597071691744205,"impliedVol":0.1441,"impliedVolPercentile":0.652},"requestUrl":"/m/hq/s/PTH","defaultTab":"news","newsList":[{"id":"2581885921","title":"Ascendis Pharma announces new pooled analysis on TransCon PTH","url":"https://stock-news.laohu8.com/highlight/detail?id=2581885921","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581885921?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:35","pubTimestamp":1762522513,"startTime":"0","endTime":"0","summary":"Ascendis Pharma (ASND) announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal function in adults wit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-announces-new-pooled-analysis-on-transcon-pth-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-announces-new-pooled-analysis-on-transcon-pth-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","BK4585","BK4139","LU0889565916.HKD","ASND","PTH","LU0320765992.SGD"],"gpt_icon":0},{"id":"2579297718","title":"BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2579297718","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579297718?lang=en_us&edition=fundamental","pubTime":"2025-10-29 19:00","pubTimestamp":1761735600,"startTime":"0","endTime":"0","summary":"- The CALIBRATE study of encaleret for patients with ADH1 met all pre-specified primary and key secondary efficacy endpoints - The primary endpoint was met with 76% of participants administered encale","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176268/0/en/BridgeBio-Reports-Positive-Phase-3-Topline-Results-for-Encaleret-in-Patients-with-Autosomal-Dominant-Hypocalcemia-Type-1.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH"],"gpt_icon":0},{"id":"2569867037","title":"MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension","url":"https://stock-news.laohu8.com/highlight/detail?id=2569867037","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569867037?lang=en_us&edition=fundamental","pubTime":"2025-09-22 19:00","pubTimestamp":1758538800,"startTime":"0","endTime":"0","summary":"Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE) Positive findings in bone","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/22/3153770/0/en/MBX-Biosciences-Announces-Once-Weekly-Canvuparatide-Achieved-Primary-Endpoint-in-Phase-2-Trial-with-63-Responder-Rate-at-12-Weeks-79-Responder-Rate-at-6-Months-in-Open-Label-Extens.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4092","MBX","BK4007","BK4181","HP","PK","PTH","BK4218","PRN","PBH"],"gpt_icon":0},{"id":"2565851094","title":"Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism","url":"https://stock-news.laohu8.com/highlight/detail?id=2565851094","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565851094?lang=en_us&edition=fundamental","pubTime":"2025-09-07 02:30","pubTimestamp":1757183400,"startTime":"0","endTime":"0","summary":"- 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5 days of encaleret treatment initiation compared to 0%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/06/3145695/0/en/Encaleret-Showed-Parathyroid-Hormone-Independent-Normalization-of-Blood-and-Urine-Calcium-in-Phase-2-Proof-of-Concept-Study-in-Post-Surgical-Hypoparathyroidism.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4212","POST","PTH","PACI.U"],"gpt_icon":0},{"id":"2564338327","title":"Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2564338327","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564338327?lang=en_us&edition=fundamental","pubTime":"2025-09-03 04:01","pubTimestamp":1756843260,"startTime":"0","endTime":"0","summary":"COPENHAGEN, Denmark, Sept.  02, 2025  (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced three oral presentations of its latest achondroplasia and hypoparathyroidism data at ASBMR ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/02/3143121/0/en/Ascendis-to-Share-Latest-Endocrinology-Rare-Disease-Data-in-3-Oral-Presentations-at-ASBMR-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH"],"gpt_icon":0},{"id":"2557680865","title":"Press Release: MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2557680865","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557680865?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:00","pubTimestamp":1754568000,"startTime":"0","endTime":"0","summary":"Topline results for the Phase 2 Avail trial of canvuparatide in hypoparathyroidism on track for Q3 2025. Imapextide  Phase 2a trial initiation in patients with post-bariatric hypoglycemia anticipated in Q3 2025. $224.9 million in cash, cash equivalents and marketable securities as of June 30, 2025; expected to support operations into mid-2027. \"We are pleased to report continuous clinical development progress across our entire pipeline of Precision Endocrine Peptide  product candidates with a number of value-creating milestones anticipated in the second half of this year,\" said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. \"We look forward to sharing topline results from our Phase 2 Avail trial of canvuparatide in hypoparathyroidism this quarter. In addition, we are on track to initiate a Phase 2a clinical trial for imapextide, a peptide therapy for the treatment of post-bariatric hypoglycemia, and a Phase 1 trial evaluating MBX 4291 in patients with obesity,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN8TJ469.HKD","LU1894683264.USD","LU0234572021.USD","PEP","03160","BK4534","HP","PBH","BK4177","BK4555","LU1894683348.USD","BK4550","BK4585","BK4604","TM","LU1162221912.USD","LU1244550577.SGD","BK4566","LU1929549753.HKD","BK4581","BK4007","IE00B3T34201.USD","LU1244550494.USD","LU0320765646.SGD","LU0098860793.USD","IE00BLSP4452.SGD","IE00BBT3K403.USD","LU1244550221.USD","BK4533","BK4099","BK4504","IE00BLSP4239.USD","PTH","MBX","BK4092","BK4588"],"gpt_icon":0},{"id":"2551135998","title":"New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life","url":"https://stock-news.laohu8.com/highlight/detail?id=2551135998","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551135998?lang=en_us&edition=fundamental","pubTime":"2025-07-15 04:01","pubTimestamp":1752523260,"startTime":"0","endTime":"0","summary":"COPENHAGEN, Denmark, July  14, 2025  (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 156 of its Phase 3 PaTHway Trial confirming that long-term treatment with","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/14/3115141/0/en/New-3-Year-Phase-3-Data-Confirmed-Sustained-Response-to-TransCon-PTH-Palopegteriparatide-Therapy-in-Adults-with-Hypoparathyroidism-Including-Improvements-in-Biochemistries-Kidney-F.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH"],"gpt_icon":0},{"id":"2549557734","title":"Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2549557734","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549557734?lang=en_us&edition=fundamental","pubTime":"2025-07-08 04:01","pubTimestamp":1751918460,"startTime":"0","endTime":"0","summary":"COPENHAGEN, Denmark, July  07, 2025  (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced two oral presentations at ENDO 2025, the annual meeting of the Endocrine Society being held ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/07/3111287/0/en/Ascendis-to-Share-Its-Latest-Endocrinology-Rare-Disease-Data-at-ENDO-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","PTH","ENDO"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0126},{"period":"1month","weight":0.0741},{"period":"3month","weight":0.2952},{"period":"6month","weight":0.361},{"period":"1year","weight":0.2529},{"period":"ytd","weight":0.3077}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of at least 30 securities of companies in the healthcare sector that have powerful relative strength or \"momentum\" characteristics.","yearOnYearQuotes":[{"month":1,"riseRate":0.631579,"avgChangeRate":0.004391},{"month":2,"riseRate":0.578947,"avgChangeRate":0.004927},{"month":3,"riseRate":0.526316,"avgChangeRate":0.002313},{"month":4,"riseRate":0.631579,"avgChangeRate":0.009459},{"month":5,"riseRate":0.631579,"avgChangeRate":0.019343},{"month":6,"riseRate":0.631579,"avgChangeRate":0.02766},{"month":7,"riseRate":0.578947,"avgChangeRate":0.016252},{"month":8,"riseRate":0.578947,"avgChangeRate":0.009248},{"month":9,"riseRate":0.526316,"avgChangeRate":-0.002121},{"month":10,"riseRate":0.631579,"avgChangeRate":-0.013459},{"month":11,"riseRate":0.75,"avgChangeRate":0.028691},{"month":12,"riseRate":0.6,"avgChangeRate":0.01236}],"exchange":"ARCA","name":"Invesco Dorsey Wright Healthcare Momentum ETF","nameEN":"Invesco Dorsey Wright Healthcare Momentum ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Invesco Dorsey Wright Healthcare Momentum ETF(PTH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Invesco Dorsey Wright Healthcare Momentum ETF(PTH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Invesco Dorsey Wright Healthcare Momentum ETF,PTH,Invesco Dorsey Wright Healthcare Momentum ETF股票,Invesco Dorsey Wright Healthcare Momentum ETF股票老虎,Invesco Dorsey Wright Healthcare Momentum ETF股票老虎国际,Invesco Dorsey Wright Healthcare Momentum ETF行情,Invesco Dorsey Wright Healthcare Momentum ETF股票行情,Invesco Dorsey Wright Healthcare Momentum ETF股价,Invesco Dorsey Wright Healthcare Momentum ETF股市,Invesco Dorsey Wright Healthcare Momentum ETF股票价格,Invesco Dorsey Wright Healthcare Momentum ETF股票交易,Invesco Dorsey Wright Healthcare Momentum ETF股票购买,Invesco Dorsey Wright Healthcare Momentum ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Invesco Dorsey Wright Healthcare Momentum ETF(PTH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Invesco Dorsey Wright Healthcare Momentum ETF(PTH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}